Latest News - Mobius Therapeutics

Tuesday, October 31, 2017 | Glaucoma, Mobius Therapeutics

Mitosol's Orphan Drug Designation is Expanded for All Glaucoma Surgery

Mobius Therapeutics has expanded its orphan drug designation from the FDA for its platform product, Mitosol, to now read "Treatment of refractory glaucoma as an adjunct to surgery." By expan…

Read the full story

Tuesday, January 06, 2015 | Glaucoma, Mobius Therapeutics

Mitosol Receives Key Reimbursement Assurance for 2015

Mobius Therapeutics has received a renewal of reimbursement for Mitosol (mitomycin) kit for ophthalmic use in 2015, according to a company news release. After reviewing the final OPPS/ASC rule from th…

Read the full story